We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agilent Q4 Earnings Match Estimates, Revenues Up Y/Y, Shares Fall
Read MoreHide Full Article
Key Takeaways
Agilent's Q4 earnings were in line with estimates and reported 9.4% revenue growth.
Strong LDG and ACG sales drove the top-line, with both segments rising on reported and core bases.
Agilent issued Q1 and full-year 2026 guidance, indicating continued reported and core revenue growth.
Agilent Technologies (A - Free Report) reported fourth-quarter fiscal 2025 earnings of $1.59 per share, which were in line with the Zacks Consensus Estimate. The figure increased 8.9% year over year.
Revenues of $1.86 billion surpassed the Zacks Consensus Estimate by 1.49%. The top line increased 9.4% on a reported basis and 7.2% on a core basis (excluding acquisitions and divestitures) year over year.
Agilent shares are down 1.13% in the pre-market trading.
Agilent’s Q4 Top-Line Details
The company operates through three reporting segments—Life Sciences and Diagnostics Markets Group (“LDG”), Agilent CrossLab Group (“ACG”) and Applied Markets Group (“AMG”).
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
LDG: The segment generated $755 million and accounted for 40.6% of the company’s total revenues. This represented a 15% increase on a reported basis and an 11% rise on a core basis year over year.
ACG: Revenues from the segment were $755 million, accounting for 40.6% of the total revenues. The top line grew 7% on a reported basis and 6% on a core basis year over year.
AMG: Revenues increased 4% year over year to $351 million on a reported and 3% on a core basis, accounting for the remaining 18.9% of the total revenues.
Agilent’s Q4 Operating Results
For the fourth quarter of fiscal 2025, the LDG segment’s gross margin contracted 90 basis points (bps) year over year to 52.9%. ACG’s gross margin decreased 140 bps year over year to 54.9%, while AMG’s gross margin declined 40 bps year over year to 54.6%.
Research and development (R&D) expenses on a non-GAAP basis were $116 million, up 6.4% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose to $386 million, marking a 6.6% increase from the prior-year quarter.
As a percentage of revenues, Research and development expenses fell 20 bps year over year to 6.2%, while selling, general and administrative expenses fell 50 bps year over year to 20.7%.
The non-GAAP operating margin of 27.1% for the fiscal fourth quarter contracted 30 bps on a year-over-year basis.
Segment-wise, LDG operating margin increased 130 bps year over year to 22.7%. ACG’s operating margin fell 130 bps year over year to 32.5%. Meanwhile, AMG’s operating margin contracted 70 bps year over year to 24.7%.
A’s Balance Sheet Details
As of Oct. 31, 2025, Agilent’s cash and cash equivalents were $1.78 billion, up from $1.54 billion as of July 31, 2025.
The long-term debt was $3.05 billion as of Oct. 31, 2025, compared with $3.35 billion as of July 31, 2025.
Agilent’s Q1 & FY26 Guidance
For the first quarter of fiscal 2026, Agilent expects revenues in the range of $1.79-$1.82 billion, indicating a rise of 6% to 8% on a reported basis and 4% to 6% on a core basis. Non-GAAP earnings are expected to be between $1.35 per share and $1.38 per share.
For fiscal 2026, Agilent expects revenues between $7.3 billion and $7.4 billion, implying an increase of 5-7% on a reported basis and 4-6% on a core basis. The company expects non-GAAP earnings between $5.86 per share and $6.00 per share.
A’s Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #3 (Hold).
BioLife Solutions shares have gained 1.5% in the year-to-date period. The Zacks Consensus Estimate for BioLife Solutions' 2025 earnings is pegged at 7 cents per share, up by a couple of pennies over the past 30 days, suggesting growth of 200% from the year-ago quarter’s reported figure.
Phibro Animal Health shares have surged 105.2% in the year-to-date period. The Zacks Consensus Estimate for Phibro Animal Health’s 2025 earnings is pegged at $2.76 per share, up by 9.09% over the past 30 days, suggesting year-over-year growth of 32.06%.
Medtronic shares have surged 29.2% in the year-to-date period. The Zacks Consensus Estimate for Medtronic's fiscal 2026 earnings is pegged at $5.65 per share, implying a rise of 2.91% from the year-ago quarter’s levels.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agilent Q4 Earnings Match Estimates, Revenues Up Y/Y, Shares Fall
Key Takeaways
Agilent Technologies (A - Free Report) reported fourth-quarter fiscal 2025 earnings of $1.59 per share, which were in line with the Zacks Consensus Estimate. The figure increased 8.9% year over year.
Revenues of $1.86 billion surpassed the Zacks Consensus Estimate by 1.49%. The top line increased 9.4% on a reported basis and 7.2% on a core basis (excluding acquisitions and divestitures) year over year.
Agilent shares are down 1.13% in the pre-market trading.
Agilent’s Q4 Top-Line Details
The company operates through three reporting segments—Life Sciences and Diagnostics Markets Group (“LDG”), Agilent CrossLab Group (“ACG”) and Applied Markets Group (“AMG”).
Agilent Technologies, Inc. Price, Consensus and EPS Surprise
Agilent Technologies, Inc. price-consensus-eps-surprise-chart | Agilent Technologies, Inc. Quote
LDG: The segment generated $755 million and accounted for 40.6% of the company’s total revenues. This represented a 15% increase on a reported basis and an 11% rise on a core basis year over year.
ACG: Revenues from the segment were $755 million, accounting for 40.6% of the total revenues. The top line grew 7% on a reported basis and 6% on a core basis year over year.
AMG: Revenues increased 4% year over year to $351 million on a reported and 3% on a core basis, accounting for the remaining 18.9% of the total revenues.
Agilent’s Q4 Operating Results
For the fourth quarter of fiscal 2025, the LDG segment’s gross margin contracted 90 basis points (bps) year over year to 52.9%. ACG’s gross margin decreased 140 bps year over year to 54.9%, while AMG’s gross margin declined 40 bps year over year to 54.6%.
Research and development (R&D) expenses on a non-GAAP basis were $116 million, up 6.4% from the prior-year quarter. Selling, general and administrative (SG&A) expenses on a non-GAAP basis rose to $386 million, marking a 6.6% increase from the prior-year quarter.
As a percentage of revenues, Research and development expenses fell 20 bps year over year to 6.2%, while selling, general and administrative expenses fell 50 bps year over year to 20.7%.
The non-GAAP operating margin of 27.1% for the fiscal fourth quarter contracted 30 bps on a year-over-year basis.
Segment-wise, LDG operating margin increased 130 bps year over year to 22.7%. ACG’s operating margin fell 130 bps year over year to 32.5%. Meanwhile, AMG’s operating margin contracted 70 bps year over year to 24.7%.
A’s Balance Sheet Details
As of Oct. 31, 2025, Agilent’s cash and cash equivalents were $1.78 billion, up from $1.54 billion as of July 31, 2025.
The long-term debt was $3.05 billion as of Oct. 31, 2025, compared with $3.35 billion as of July 31, 2025.
Agilent’s Q1 & FY26 Guidance
For the first quarter of fiscal 2026, Agilent expects revenues in the range of $1.79-$1.82 billion, indicating a rise of 6% to 8% on a reported basis and 4% to 6% on a core basis. Non-GAAP earnings are expected to be between $1.35 per share and $1.38 per share.
For fiscal 2026, Agilent expects revenues between $7.3 billion and $7.4 billion, implying an increase of 5-7% on a reported basis and 4-6% on a core basis. The company expects non-GAAP earnings between $5.86 per share and $6.00 per share.
A’s Zacks Rank & Stocks to Consider
Currently, Agilent carries a Zacks Rank #3 (Hold).
BioLife Solutions (BLFS - Free Report) , Phibro Animal Health (PAHC - Free Report) and Medtronic (MDT - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector. While BLFS and PAHC sport a Zacks Rank #1 (Strong Buy), MDT carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
BioLife Solutions shares have gained 1.5% in the year-to-date period. The Zacks Consensus Estimate for BioLife Solutions' 2025 earnings is pegged at 7 cents per share, up by a couple of pennies over the past 30 days, suggesting growth of 200% from the year-ago quarter’s reported figure.
Phibro Animal Health shares have surged 105.2% in the year-to-date period. The Zacks Consensus Estimate for Phibro Animal Health’s 2025 earnings is pegged at $2.76 per share, up by 9.09% over the past 30 days, suggesting year-over-year growth of 32.06%.
Medtronic shares have surged 29.2% in the year-to-date period. The Zacks Consensus Estimate for Medtronic's fiscal 2026 earnings is pegged at $5.65 per share, implying a rise of 2.91% from the year-ago quarter’s levels.